News|Videos|November 16, 2023
CAR T-Cell and Loncastuximab in DLBCL: Clinical Insights and Treatment Considerations
Author(s)Matthew A. Lunning, DO, FACP
A comprehensive exploration of CAR T-cell therapy and additional agents such as loncastuximab in relapsed/refractory DLBCL, emphasizing clinical findings and treatment considerations.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Advertisement
Advertisement